Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma

Head and Neck

Volumn 38, Issue , 2016, Pages E494-E501

  Whiteside, Theresa L ^a,b   Ferris, Robert L ^a,b   Szczepanski, Miroslaw ^b   Tublin, Mitchell ^a   Kiss, Joseph ^a,b   Johnson, Rita ^b   Johnson, Jonas T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

apoptotic tumor cells; dendritic cells; head and neck squamous cell carcinoma (HNSCC); T cell responses; vaccine

Indexed keywords

APOPTOTIC TUMOR CELL VACCINE; CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE;

ADVANCED CANCER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER STAGING; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MONOCYTE; PILOT STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VACCINE PRODUCTION; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; HYPERSENSITIVITY, DELAYED; PILOT PROJECTS;

EID: 84973481497     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24025     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Shuman AG, McKiernan JT, Thomas D, et al., Outcomes of a head and neck cancer screening clinic. Oral Oncol 2013; 49: 1136-1140.
3. Mouw KW, Solanki AA, Stenson KM, et al., Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol 2012; 48: 1025-1030.
4. Brockstein BE, Vokes EE,. Head and neck cancer in 2010: maximizing survival and minimizing toxicity. Nat Rev Clin Oncol 2011; 8: 72-74.
5. Argiris A, Heron DE, Smith RP, et al., Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28: 5294-5300.
6. Gao J, Panizza B, Johnson NW, Coman S, Clough AR,. Basic consideration of research strategies for head and neck cancer. Front Med 2012; 6: 339-353.
7. Berzofsky JA, Terabe M, Wood LV,. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol 2012; 39: 348-357.
8. Whiteside TL,. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets 2007; 7: 633-642.
9. Herold-Mende C, Karcher J, Dyckhoff G, Schirrmacher V,. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryngol 2005; 62: 173-183.
10. Karcher J, Dyckhoff G, Beckhove P, et al., Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 2004; 64: 8057-8061.
11. DeLeo AB, Whiteside TL,. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 2008; 7: 1031-1040.
12. Schuler PJ, Harasymczuk M, Visus C, et al., Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20: 2433-2444.
13. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G,. Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 2009; 9: 1043-1055.
14. Curigliano G, Rescigno M, Goldhirsch A,. Immunology and breast cancer: therapeutic cancer vaccines. Breast 2007; 16 Suppl 2: S20-S26.
15. Elder EM, Whiteside TL,. Processing of tumors for vaccine and/or tumor infiltrating lymphocytes. In:, Friedman H, Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM, editors. Manual of Clinical Laboratory Immunology, fourth edition. Washington, DC: American Society of Microbiology; 1992. pp 817-819.
16. Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V,. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986; 90: 221-233.
17. Whiteside TL,. Evaluation of dendritic cell products generated for human therapy and post-treatment immune monitoring. In: Advances in Vaccine Development and Manufacturing. Bannockburn, IL: BioPharm International; 2008. pp 2-17.
18. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL,. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000; 60: 3542-3549.
19. Butterfield LH, Gooding W, Whiteside TL,. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother 2008; 31: 89-100.
20. Szczepanski MJ, Czystowska M, Szajnik M, et al., Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69: 3105-3113.
21. Schaefer C, Butterfield LH, Lee S, et al., Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer 2012; 131: 874-884.
22. Hoffmann TK, Dworacki G, Tsukihiro T, et al., Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-2562.
23. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL,. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6301-6311.
24. López-Albaitero A, Nayak JV, Ogino T, et al., Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 3402-3409.
25. Wanebo HJ, Hilal EY, Strong EW, Pinsky CM, Mike V, Oettgen HF,. Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results Cancer Res 1978; 68: 324-333.
26. Miller MJ, Foy KC, Kaumaya PT,. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 2013; 15: 166-176.
27. Lucs AV, Saltman B, Chung CH, Steinberg BM, Schwartz DL,. Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head Neck 2013; 35: 294-306.
28. Keenan BP, Jaffee EM,. Whole cell vaccines-past progress and future strategies. Semin Oncol 2012; 39: 276-286.
29. Dillman RO, Depriest C, McClure SE,. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm 2014; 29: 53-57.
30. Whiteside TL,. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95-105.
31. Galon J, Pagès F, Marincola FM, et al., Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.